Completed

NCT Number: NCT00901888

Interaction of Apelin and Angiotensin in the Human Forearm Circulation

The apelin-APJ system is a relatively new discovery. It has generated interest in part due to it's apparent ability to counteract the renin-angiotensin system, which is frequently overactive in many cardiovascular disease.

Angiotensin has a powerful ability to cause blood vessels constrict and reduces their diameter. One of the actions of apelin is to cause blood vessels to relax and the investigators specifically wish test the hypothesis that apelin will cause blood vessels constricted by angiotensin II to relax.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Heart Disease Aneurysm Cardiovascular Diseases Heart Diseases Vascular Diseases Vasodilation

Age range

18 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Clincial Research Facility, Royal Infirmary of Edinburgh, 51 Little France Cresc

Edinburgh, EH16 4SA, United Kingdom

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

> 18 years old

Exclusion criteria

Lack of informed consent
Age < 18 years,
Current involvement in other research studies,
Systolic blood pressure >190 mmHg or <100 mmHg
Malignant arrhythmias
Renal or hepatic failure
Haemodynamically significant aortic stenosis
Severe or significant co morbidity
Women of childbearing potential.
Any regular medication
Previous history of any cardiovascular disease

Treatment and study plan

Apelin infusion

Drug

Infusion of up to 10picmol/min will be administered intra-arterially to induce vasoconstriction. Thereafter infusions of apelin (0.1, 1.0, 3.0nmol/min) will be given for 6mins each. During the same study, sodium nitroprusside will given (1.0, 2.0, 4.0 microg/min) for 6mins.

Sodium nitroprusside infusion

Drug

Infusion of up to 150-600picmol/min will be administered intra-arterially to induce vasoconstriction. Thereafter infusions of apelin (0.1, 1.0, 3.0nmol/min) will be given for 6mins each. During the same study, sodium nitroprusside will given (1.0, 2.0, 4.0 microg/min) for 6mins.

Primary outcomes

Change in apelin mediated forearm blood flow

Time frame: 12 months

Secondary outcomes

Change in local and systemic plasma apelin concentration in response angiotensin II infusion

Time frame: 12 months

Sponsors and collaborators

Lead sponsor

University of Edinburgh

Other

Collaborators

NHS Lothian

Registry information

Official study title

Investigating the Interaction of Apelin and Angiotensin II Peripheral Resistance Vessels in Vivo in Man

Important dates

Study start: 2009
Primary completion: 2010
Study completion: 2010
First posted: May 14, 2009
Registry last updated: Aug 10, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed